SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy
10 septembre 2014 mis à jour par: Hoffmann-La Roche
A Comparative Study to Assess the Effect of Retreatment With 2 Doses of MabThera on Disease Activity Score in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response or Intolerance to antiTNF-alfa Therapy.(SMART)
This study will compare the efficacy and safety of re-treatment with 2 doses of MabThera (rituximab) in patients with active rheumatoid arthritis (RA) who have previously experienced an inadequate response or intolerance to anti-tumor necrosis factor (anti-TNF) therapies etanercept, infliximab or adalimumab therapy.
All patients will receive infusions of 1000 mg intravenous (IV) MabThera on Days 1 and 15; at Week 24 patients who have demonstrated a moderate or good response will be randomized to receive re-treatment with either 1 or 2 additional infusions of 1000 mg IV MabThera.
The anticipated time on study treatment is 2+ years, and the target sample size is 100-500 individuals.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Type d'étude
Interventionnel
Inscription (Réel)
224
Phase
- Phase 3
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Abbeville, France, 80142
-
Agen, France, 47923
-
Aix En Provence, France, 13616
-
Aix Les Bains, France, 73106
-
Amiens, France, 80054
-
Belfort, France, 90016
-
Berck, France, 62600
-
Bobigny, France, 93009
-
Bois-guillaume, France, 76233
-
Boulogne-billancourt, France, 92104
-
Brest, France, 29609
-
Caen, France, 14033
-
Cahors, France, 46005
-
Clermont-ferrand, France, 63003
-
Corbeil-essonnes, France, 91106
-
Echirolles, France, 38434
-
La Roche Sur Yon, France, 85925
-
Le Kremlin Bicetre, France, 94275
-
Libourne, France, 33505
-
Lievin, France, 62800
-
Lille, France, 59037
-
Limoges, France, 87042
-
Lomme, France, 59462
-
Lyon, France, 69365
-
Marseille, France, 13013
-
Montivilliers, France, 76290
-
Montpellier, France, 34295
-
Nantes, France, 44035
-
Narbonne, France, 11108
-
Nice, France, 06202
-
PAU, France, 64046
-
Paris, France, 75651
-
Paris, France, 75475
-
Paris, France, 75674
-
Paris, France, 75571
-
Paris, France, 75679
-
Paris, France, 75877
-
Paris, France, 75019
-
Perpignan, France, 66046
-
Pessac, France, 33600
-
Pierre Benite, France, 69495
-
Poitiers, France, 86021
-
Reims, France, 51100
-
Rennes, France, 35203
-
Saint-etienne, France, 4200
-
Strasbourg, France, 67098
-
Toulon, France, 83100
-
Toulouse, France, 31059
-
Toulouse, France, 31054
-
Valence, France, 26000
-
Valenciennes, France, 59322
-
Vandoeuvre-les-nancy, France, 54511
-
Vannes, France, 56017
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
18 ans et plus (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- Adult patients >18 years of age
- RA for >=6 months
- Receiving outpatient treatment
- Ongoing treatment with methotrexate for >=3 months, stable for >=1 month
- Inadequate response or intolerance to etanercept, infliximab or adalimumab
Exclusion Criteria:
- Previous treatment with MabThera
- Concurrent treatment with any anti TNF-alfa therapy or biologic therapy
- Previous treatment with any investigational cell-depleting therapies
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: A
1000 mg IV rituximab
|
Arm A: 1000 mg IV (one infusion) every 2 months \nArm B: 2 x 1000 mg IV (2 infusions) every 2 months
Autres noms:
|
|
Expérimental: B
2 x 1000 mg IV rituximab
|
Arm A: 1000 mg IV (one infusion) every 2 months \nArm B: 2 x 1000 mg IV (2 infusions) every 2 months
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Disease Activity Score Based on 28-Joints Count and C-Reactive Protein (DAS28-CRP) Area Under the Curve (AUC) at Week 104
Délai: Week 104
|
DAS28-CRP was based on joint counts, overall participant assessment, and serum CRP levels (measured in milligrams per liter [mg/L]) at each visit.
Joint counts included swollen joint count (SJC) and tender joint count (TJC).
Total score range was 0 to 9.4; a higher score indicated more disease activity.
DAS28-CRP less than or equal to (≤)3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity, and less than (<)2.6 equals (=) remission.
The AUC of all DAS28-CRP values between Day 1 and Week 104 (15 values of protocol visits) was calculated using the trapeze method (AUC between t1 and t2=(t2-t1)*((DAS28-CRP at t1 + DAS28-CRP at t2)/2).
The true visit dates were used to calculate the time between 2 DAS28-CRP evaluations.
All the AUC were censored at Week 104 (linear extrapolation using the 2 last DAS28-CRP values (Weeks 96 and 104) to obtain the "true" DAS28-CRP value at the "true" Week 104).
|
Week 104
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
DAS28-CRP During the Initial Treatment
Délai: Days 1 and 15, and Weeks 6, 12, and 24
|
Mean DAS28-CRP at Week 24 of the Initial Treatment study.
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit.
Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L).
Total score range: 0 to 9.4, higher score indicated more disease activity.
DAS28-CRP ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity, and <2.6=remission.
|
Days 1 and 15, and Weeks 6, 12, and 24
|
|
DAS28-CRP and Changes From Baseline to Week 24 in DAS28-CRP by Retreatment Course
Délai: Day 1, 24 weeks following each infusion up to 72 Weeks
|
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit.
Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L).
Total score range=0 to 9.4; a higher score indicated more disease activity.
A DAS28-CRP score of ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity, and <2.6=remission.
|
Day 1, 24 weeks following each infusion up to 72 Weeks
|
|
Percentage of Participants Achieving Clinical Remission (DAS28-CRP <2.6) or Low Disease Activity (DAS28-CRP ≤3.2)
Délai: Week 24 of the Initial Treatment, 24 weeks after first retreatment, and 24 weeks after second retreatment
|
Percentage of participants with clinical remission and low disease activity as measured by DAS28-CRP for Arm A and Arm B at Week 24 of the Initial Treatment, at 24 weeks after first re-treatment, and at 24 weeks after second retreatment.
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit.
Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L).
Total score range=0 to 9.4; a higher score indicated more disease activity.
A DAS28-CRP score of ≤3.2 implied low disease activity and <2.6 = remission.
|
Week 24 of the Initial Treatment, 24 weeks after first retreatment, and 24 weeks after second retreatment
|
|
DAS28-CRP AUC Weighted Time
Délai: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
|
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit.
Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L).
Total score range=0 to 9.4; a higher score indicated more disease activity.
A DAS28-CRP score of ≤3.2 implied low disease activity, >3.2 to 5.1 implied moderate to high disease activity, and <2.6=remission.
|
Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
|
|
Time to Achieve DAS28-CRP Remission After the First Course
Délai: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
|
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit.
Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L).
Total score range=0 to 9.4; a higher score indicated more disease activity.
A DAS28-CRP <2.6=remission.
|
Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
|
|
Time to Achieve DAS28-CRP Remission After Retreatment
Délai: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
|
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit.
Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L).
Total score range=0 to 9.4; a higher score indicated more disease activity.
A DAS28-CRP <2.6=remission.
|
Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
|
|
Time to Achieve DAS28-CRP ≤3.2 After the First Course of Treatment
Délai: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
|
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit.
Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L).
Total score range=0 to 9.4; a higher score indicated more disease activity.
A DAS28-CRP score of ≤3.2 implied low disease activity.
|
Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
|
|
Time to Achieve DAS28-CRP ≤3.2 After Retreatment
Délai: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
|
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit.
Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L).
Total score range=0 to 9.4; a higher score indicated more disease activity.
A DAS28-CRP score of ≤3.2 implied low disease activity.
|
Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
|
|
Duration of DAS28-CRP Remission After the First Course of Treatment
Délai: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
|
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit.
Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L).
Total score range=0 to 9.4; a higher score indicated more disease activity.
A DAS28-CRP <2.6=remission.
|
Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
|
|
Duration of DAS28-CRP Remission After Retreatment
Délai: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
|
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit.
Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L).
Total score range=0 to 9.4; a higher score indicated more disease activity.
A DAS28-CRP <2.6=remission.
|
Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
|
|
Duration of DAS28-CRP ≤3.2 After the First Course of Treatment
Délai: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
|
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit.
Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L).
Total score range=0 to 9.4; a higher score indicated more disease activity.
A DAS28-CRP score of ≤3.2 implied low disease activity.
|
Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
|
|
Duration of DAS28-CRP ≤3.2 After Retreatment
Délai: Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
|
DAS28-CRP was based on joint counts, overall participant assessment, and the serum CRP level at each visit.
Joint counts included SJC and TJC using the 28 joints count and CRP (mg/L).
Total score range=0 to 9.4; a higher score indicated more disease activity.
A DAS28-CRP score of ≤3.2 implied low disease activity.
|
Days 1 and 15, Weeks 6, 12, and 24 and every 8 weeks thereafter through Week 104
|
|
Percentage of Participants Achieving American College of Rheumatology 20%, 50%, and 70% Improvement (ACR20/ACR50/ACR70)
Délai: Week 24 of the initial treatment, 24 weeks after first retreatment, and 24 weeks after second retreatment
|
ACR20/50/70 response defined as ≥20%, 50%, or 70% improvement, respectively, in TJC and SJC, and ≥20%, 50%, or 70% improvement, respectively, in at least 3 of 5 remaining ACR core measures: Patient Global Assessment of Pain, Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity (on a visual analog scale [VAS]); Health Assessment Questionnaire-Disability Index (HAQ-DI); and CRP.
|
Week 24 of the initial treatment, 24 weeks after first retreatment, and 24 weeks after second retreatment
|
|
Percentage of Participants Achieving a Response During Initial Treatment by European League Against Rheumatism (EULAR) Category
Délai: Day 15, Weeks 6, 12, and 24
|
DAS28-based EULAR response criteria were used to measure individual response as no response, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached.
Good responders = change from baseline >1.2 with a DAS28 score of ≤3.2; moderate responders = change from baseline >1.2 with a DAS28 score of >3.2 to ≤ 5.1 or change from baseline >0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders = change from baseline ≤0.6 or change from baseline >0.6 and ≤ 1.2 with a DAS28 score of >5.1.
|
Day 15, Weeks 6, 12, and 24
|
|
Percentage of Participants Achieving a Response During Retreatment by EULAR Category
Délai: Week 24, 24 weeks after 1st retreatment, 24 weeks after 2nd retreatment
|
DAS28-based EULAR response criteria were used to measure individual response as no response, good, and moderate, depending on the extent of change from baseline and the level of disease activity reached.
Good responders = change from baseline >1.2 with a DAS28 score of ≤3.2; moderate responders = change from baseline >1.2 with a DAS28 score of >3.2 to ≤ 5.1 or change from baseline >0.6 to ≤1.2 with a DAS28 score of ≤5.1; non-responders = change from baseline ≤0.6 or change from baseline >0.6 and ≤ 1.2 with a DAS28 score of >5.1.
|
Week 24, 24 weeks after 1st retreatment, 24 weeks after 2nd retreatment
|
|
Percentage of Participants With Rheumatoid Factor (RF) at 24 Weeks After Treatment
Délai: Week 24 of the initial treatment, 24 weeks after first re-treatment, and 24 weeks after second retreatment
|
RF is the auto antibody directed against immunoglobulin G (IgG) and its concentration is observed in human serum or plasma.
RF value higher than 20 international units per milliliter (IU/mL) is considered positive.
|
Week 24 of the initial treatment, 24 weeks after first re-treatment, and 24 weeks after second retreatment
|
|
Percentage of Participants With Anti-cyclic Citrullinated Protein (Anti-CCP) Antibodies at 24 Weeks After Treatment
Délai: Week 24 of the initial treatment, 24 weeks after first re-treatment, and 24 weeks after second retreatment
|
Anti-CCP antibodies are auto antibodies (antibodies directed against 1 or more of an individual's own proteins) that are frequently detected in the blood of rheumatoid arthritis participants.
Anti-CCP antibodies value higher than 10 U/mL is considered positive.
|
Week 24 of the initial treatment, 24 weeks after first re-treatment, and 24 weeks after second retreatment
|
|
Physician's Global Assessment of Disease Activity
Délai: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
|
The Physician's Global Assessment of disease activity is assessed on a 0 to 100 millimeter (mm) horizontal VAS by the physician.
The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity).
Physicians were asked to mark the line and the distance from the left edge was measured.
Higher values correspond to worst state of participant (high disease activity).
|
Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
|
|
Patient Global Assessment of Disease Activity
Délai: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
|
The Patient's Global Assessment of Disease Activity is assessed on a 0 to 100 mm horizontal VAS by the participant.
The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity).
Higher values correspond to worst state of participant (high disease activity).
|
Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
|
|
Patient's Global Assessment of Pain
Délai: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
|
The participants assessed their pain over the past 24 hours on a 0 to 100 mm horizontal VAS.
The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain".
Participants were asked to mark the line and the distance from the left edge was measured.
Higher values correspond to worst state of participant (high pain levels).
|
Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
|
|
Participant Assessment of Fatigue
Délai: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
|
Participants were asked to rate their level of fatigue over the last 7 days on a 100-mm VAS.
The left-hand extreme of the line equals 0 mm, and is described as "no fatigue" and the right-hand extreme equals 100 mm as "extreme fatigue".
Participants were asked to mark the line and the distance from the left edge was measured.
Higher values correspond to worst state of participant (high levels of fatigue).
|
Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
|
|
Cortisone Intake AUC (Time- and Weight-Weighted)
Délai: Day 1 (each infusion), Week 24, Week 104
|
All cortisone intakes (in mg) were taken into account (oral, IV [including the cortisone administration before the rituximab infusion], intramuscular, and intra-articular).
|
Day 1 (each infusion), Week 24, Week 104
|
|
Total Mean Dose of Cortisone Between Week 24 and Week 104
Délai: Week 24 to Week 104
|
All cortisone intakes were taken into account, including oral, IV (including the cortisone administration before the rituximab infusion), intramuscular and intra-articular.
|
Week 24 to Week 104
|
|
HAQ-DI Scores
Délai: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
|
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week.
Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do.
Overall score was computed as the sum of domain scores and divided by the number of domains answered.
Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.
|
Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
|
|
Short Form 12 (SF-12) Physical Health Composite Score
Délai: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
|
Physical and Mental Health Composite Scores of SF-12 were computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.
|
Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
|
|
SF-12 Mental Health Composite Score
Délai: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
|
Mental Health Composite Scores of SF-12 were computed using the scores of 12 questions and range from 0 to 100, where a 0 score indicates the lowest level of health measured by the scales and 100 indicates the highest level of health.
|
Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
|
|
Medical Outcomes Study Sleep Scale (MOS-Sleep) Composite Sleep Problems 6 (SLP6) Index
Délai: Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
|
The MOS Sleep Scale measures most constructs of sleep.
The scale has a battery of questions to measure specific aspects of sleep in participants with co-morbidities.
The SLP6 index is comprised of 6 items: provides a summary of sleep problems and contains questions from the sleep disturbance, sleep adequacy, respiratory impairment, and somnolence domains.
The SLP6 index score ranges between 0 and 100, with higher values corresponding to more sleep problems.
|
Day 1 and Week 24 of initial treatment, before 1st retreatment, at 1st retreatment, and at 12 and 24 weeks after 1st retreatment
|
|
Percentage of Participants Reporting Acceptable Disease Activity Symptom State Assessed Using Patient Acceptable and Unacceptable Symptom State (PASS)
Délai: Week 24, 12 and 24 weeks after 1st retreatment
|
Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of disease activity they had during the last 48 hours.
In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered "unacceptable".
|
Week 24, 12 and 24 weeks after 1st retreatment
|
|
Patient Global Assessment of Disease Activity in Participants Reporting Acceptable Symptoms Using PASS
Délai: Week 24, 12 and 24 weeks after 1st retreatment
|
The Patient's Global Assessment of Disease Activity assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours) on a 0 to 100 mm horizontal VAS by the participant.
The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity).
Higher values correspond to worst state of participant (high disease activity).
|
Week 24, 12 and 24 weeks after 1st retreatment
|
|
Percentage of Participants With Minimum Clinically Important Improvement (MCII) in Disease Activity
Délai: Week 24, 12 and 24 weeks after 1st retreatment
|
Participants were asked how their disease activity had been during the last 48 hours compared to baseline.
Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important.
Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse-more disease activity.
|
Week 24, 12 and 24 weeks after 1st retreatment
|
|
Change From Baseline in Patient Global Assessment of Disease Activity in Participants With MCII
Délai: Baseline, Week 24, 12 and 24 weeks after 1st retreatment
|
The Patient's Global Assessment of Disease Activity was assessed in participants reporting MCII on a 0 to 100 mm horizontal VAS by the participant.
The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm as "maximum disease activity" (maximum arthritis disease activity).
Higher values correspond to worst state of participant (high disease activity).
|
Baseline, Week 24, 12 and 24 weeks after 1st retreatment
|
|
Percentage of Participants Reporting Acceptable Symptom State in Functioning Assessed Using PASS
Délai: Week 24, 12 and 24 weeks after 1st retreatment
|
Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of function they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of function they had during the last 48 hours.
In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered "unacceptable".
|
Week 24, 12 and 24 weeks after 1st retreatment
|
|
HAQ-DI Scores in Participants Reporting Acceptable Function Using PASS
Délai: Week 24, 12 and 24 weeks after 1st retreatment
|
HAQ-DI was assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of disease activity they had during the last 48 hours).
HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week.
Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do.
Overall score was computed as the sum of domain scores and divided by the number of domains answered.
Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.
|
Week 24, 12 and 24 weeks after 1st retreatment
|
|
Percentage of Participants With MCII in Functioning
Délai: Week 24, 12 and 24 weeks after 1st retreatment
|
Participants were asked how their functioning had been during the last 48 hours compared to baseline.
Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important.
Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse.
|
Week 24, 12 and 24 weeks after 1st retreatment
|
|
Change From Baseline in HAQ-DI in Participants With MCII
Délai: Baseline, Week 24, 12 and 24 weeks after 1st retreatment
|
HAQ-DI was assessed in participants with MCII.
HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week.
Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do.
Overall score was computed as the sum of domain scores and divided by the number of domains answered.
Total possible score range 0-3 where 0=least difficulty and 3 extreme difficulty.
|
Baseline, Week 24, 12 and 24 weeks after 1st retreatment
|
|
Percentage of Participants With Acceptable Symptom State in Pain Assessed Using PASS
Délai: Week 24, 12 and 24 weeks after 1st retreatment
|
Percentage of participants reporting acceptable symptom state: acceptance to remain for the rest of their lives with the level of pain they had during the last 48 hours; and unacceptable symptom state: not able to remain for the rest of their lives with the level of pain they had during the last 48 hours.
In the case of missing data, participants who withdrew from the study because of inefficacy or toxicity were considered "unacceptable".
|
Week 24, 12 and 24 weeks after 1st retreatment
|
|
Patient Global Assessment of Pain in Participants Reporting Acceptable Symptoms Using PASS
Délai: Week 24, 12 and 24 weeks after 1st retreatment
|
Patient Global Assessment of Pain assessed in participants reporting acceptable symptom state using PASS (acceptance to remain for the rest of their lives with the level of pain they had during the last 48 hours) on a 0 to 100 mm horizontal VAS by the participant.
The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain".
Higher values correspond to worst state of participant (high pain levels).
|
Week 24, 12 and 24 weeks after 1st retreatment
|
|
Percentage of Participants With MCII in Pain
Délai: Week 24, 12 and 24 weeks after 1st retreatment
|
Participants were asked how their pain had been during the last 48 hours compared to baseline.
Those participants that reported improvement assessed how important this improvement was to them; range: very important, moderately important, slightly important, or not at all important.
Binary response options: 1=improved very important, or improved moderately important; 2=slightly important, not at all important, no change, or worse pain.
|
Week 24, 12 and 24 weeks after 1st retreatment
|
|
Change From Baseline in Patient Global Assessment of Pain in Participants With MCII
Délai: Baseline, Week 24, 12 and 24 weeks after 1st retreatment
|
The participants assessed their pain over the past 24 hours on a 0 to 100 mm horizontal VAS.
The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain".
Participants were asked to mark the line and the distance from the left edge was measured.
Higher values correspond to worst state of participant (high pain levels).
|
Baseline, Week 24, 12 and 24 weeks after 1st retreatment
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Publications générales
- de Jong TD, Sellam J, Agca R, Vosslamber S, Witte BI, Tsang-A-Sjoe M, Mantel E, Bijlsma JW, Voskuyl AE, Nurmohamed MT, Verweij CL, Mariette X. A multi-parameter response prediction model for rituximab in rheumatoid arthritis. Joint Bone Spine. 2018 Mar;85(2):219-226. doi: 10.1016/j.jbspin.2017.02.015. Epub 2017 Mar 28.
- Sellam J, Riviere E, Courties A, Rouzaire PO, Tolusso B, Vital EM, Emery P, Ferraccioli G, Soubrier M, Ly B, Hendel Chavez H, Taoufik Y, Dougados M, Mariette X. Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Res Ther. 2016 Dec 13;18(1):294. doi: 10.1186/s13075-016-1190-z. Erratum In: Arthritis Res Ther. 2017 Jan 23;19(1):11.
- Sellam J, Rouanet S, Hendel-Chavez H, Miceli-Richard C, Combe B, Sibilia J, Le Loet X, Tebib J, Jourdan R, Dougados M, Taoufik Y, Mariette X. CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2013 Sep;65(9):2253-61. doi: 10.1002/art.38023.
- Mariette X, Rouanet S, Sibilia J, Combe B, Le Loet X, Tebib J, Jourdan R, Dougados M. Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial. Ann Rheum Dis. 2014 Aug;73(8):1508-14. doi: 10.1136/annrheumdis-2013-203480. Epub 2013 May 30.
- Sellam J, Rouanet S, Hendel-Chavez H, Abbed K, Sibilia J, Tebib J, Le Loet X, Combe B, Dougados M, Mariette X, Taoufik Y. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2011 Dec;63(12):3692-701. doi: 10.1002/art.30599.
- Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Loet X, Tebib J, Sibilia J, Taoufik Y, Dougados M, Mariette X. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum. 2011 Apr;63(4):933-8. doi: 10.1002/art.30233.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 septembre 2006
Achèvement primaire (Réel)
1 novembre 2011
Achèvement de l'étude (Réel)
1 novembre 2011
Dates d'inscription aux études
Première soumission
18 mai 2010
Première soumission répondant aux critères de contrôle qualité
18 mai 2010
Première publication (Estimation)
19 mai 2010
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
15 septembre 2014
Dernière mise à jour soumise répondant aux critères de contrôle qualité
10 septembre 2014
Dernière vérification
1 septembre 2014
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système immunitaire
- Maladies auto-immunes
- Maladies articulaires
- Maladies musculo-squelettiques
- Maladies rhumatismales
- Maladies du tissu conjonctif
- Arthrite
- Arthrite, rhumatoïde
- Effets physiologiques des médicaments
- Agents antirhumatismaux
- Agents antinéoplasiques
- Facteurs immunologiques
- Agents antinéoplasiques immunologiques
- Rituximab
Autres numéros d'identification d'étude
- ML19895
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .